(Q38263364)

1 September 2017

1 reference

title

Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation (English)

1 reference

1 September 2017

1 reference

1 reference

Anthony H Barnett

1

1 reference

PubMed ID

25351273

1 September 2017

language of work or name

English

0 references

publication date

29 October 2014

1 reference

Expert Opinion on Drug Safety

1 September 2017

1 reference

1 September 2017

14

1 reference

1 September 2017

1

1 reference

1 September 2017

149-159

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

AACE comprehensive diabetes management algorithm 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Acute consequences of hypoglycaemia in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Diabetic nephropathy: new approaches for improving glycemic control and reducing risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Glycemic management in ESRD and earlier stages of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Hypertension in black patients: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Lactic acidosis induced by metformin: incidence, management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.971008

10.1517/14740338.2014.971008

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25351273